FK506 treatment in a Long-term chronic rejection rat model of small bowel transplantation

Yanfei Zhu; Wei Wei; Yousheng Li
June 2010
Clinical & Investigative Medicine;Jun2010, Vol. 33 Issue 3, pE168
Academic Journal
Background: Although acute rejection (AR) can be significantly improved by effective immunosuppressants, such as FK506, chronic rejection (CR) remains a major hurdle to long-term allograft survival after small bowel transplantation, in part because the pathogenic mechanisms of CR are, as yet, unknown. The rat orthotopic small bowel transplantation (OSBT) model has been used by a few researchers, but without long-term survival. Methods: Rats were randomly divided into five groups: Group 1 (n=20), sham-operation rats; Group 2 (n=20), Lewis to Lewis; Group 3 (n=20), F344 to Lewis treated with FK506 (0.3 mg/kg/day); Group 4 (n=20), F344 to Lewis with FK506 (0.5 mg/kg/day); Group 5 (n=20), F344 to Lewis with FK506 (1.0 mg/kg/day). FK506 was administrated intramuscularly to recipients on postoperative days (POD) 0-13, 20 and 27. Body weight, survival rate and histology were measured. Results: Histopathological analysis revealed distinctive abnormalities of the allograft for all animals, including changes in villous architecture, interstitial fibrosis and intimal thickening; however, survival times were significantly increased with higher doses of FK506. Rats in Group 3 and Group 4 (low and moderate FK506 doses) survived 16-18 weeks, while recipients in Group 5 (high dose) survived 24-27 weeks. Conclusion: FK506 treatment (1.0 mg/kg/day, intramuscularly administrated to recipients on POD0-13, 20 and 27) can be used effectively to establish a rat OBST model of CR that will be useful for the study of the pathogenesis of CR and the effectiveness of various drugs.


Related Articles

  • Pharmacokinetic study of tacrolimus in cystic fibrosis and non-cystic fibrosis lung transplant patients and design of Bayesian estimators using limited sampling strategies. Saint-Marcoux, Franck; Knoop, Christiane; Debord, Jean; Thiry, Philippe; Rousseau, Annick; Estenne, Marc; Marquet, Pierre // Clinical Pharmacokinetics;2005, Vol. 44 Issue 12, p1317 

    Objectives: To: (i) test different pharmacokinetic models to fit full tacrolimus concentration-time profiles; (ii) estimate the tacrolimus pharmacokinetic characteristics in stable lung transplant patients with or without cystic fibrosis (CF); (iii) compare the pharmacokinetic parameters between...

  • Tacrolimus: A Further Update of its Pharmacology and Therapeutic Use in the Management of Organ Transplantation. Plosker, G.L.; Foster, R.H. // Drugs;Feb2000, Vol. 59 Issue 2, p323 

    Tacrolimus (FK-506) is an immunosuppressant agent that acts by a variety of different mechanisms which include inhibition of calcineurin. It is used as a therapeutic alternative to cyclosporin, and therefore represents a cornerstone of immunosuppressive therapy in organ transplant recipients....

  • Addition of MMF to Tacrolimus Regimen Lowers Incidence of Rejection.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p209 

    Discusses an abstract of the article, entitled `A prospective, randomized trial of tacrolimus/prednisone versus tacrolimus/prednisone/mycophenolate mofetil in renal transplant recipients,' by R. Shapiro, M.L. Jordan, V.P. Santlebury and others, published in the 1999 journal 'Transplantation'.

  • Tacrolimus.  // Reactions Weekly;1/14/2012, Issue 1384, p54 

    The article describes the case of a 48-year-old man who developed accelerated common bile duct (CBD) stones and biliary sludge while receiving tacrolimus following two kidney transplants.

  • Tacrolimus.  // Reactions Weekly;3/24/2012, Issue 1394, p38 

    The article describes four cases of neurological toxicities that developed while patients with severe haematological malignancies were receiving tacrolimus following allogenic haematopoietic cell transplant (HCT) for profound renal failure.

  • Tacrolimus: A Further Update of its Use in the Management of Organ Transplantation. Scott, Lesley J.; McKeage, Kate; Keam, Susan J.; Plosker, Greg L. // Drugs;2003, Vol. 63 Issue 12, p1247 

    Extensive clinical use has confirmed that tacrolimus (Prograf[sup ®]) is a key option for immunosuppression after transplantation. In large, prospective, randomised, multicentre trials in adults and children receiving solid organ transplants, tacrolimus was at least as effective or provided...

  • Drug interactions with tacrolimus. van Gelder, T.; van Gelder, Teun // Drug Safety;Jul2002, Vol. 25 Issue 10, p707 

    Tacrolimus is a drug for which therapeutic drug monitoring is recommended. The existence of a wide variety of potential drug interactions further supports the current strategy of measuring whole blood tacrolimus concentrations in transplanted patients. Cytochrome P450 (CYP)3A, the major phase I...

  • No Evidence of Islet Toxicity with Long-Term Tacrolimus.  // Kidney;Sep/Oct99, Vol. 8 Issue 5, p212 

    Discusses an abstract of the article, entitled 'Long-term results of pancreas transplantation under tacrolimus immunosuppression,' M.L. Jordan, R. Shapiro, H.A. Gritsch and others, published in the 1999 journal of the 'Transplantation'.

  • CYP3A5 Genotype, but Not CYP3A4*1b, CYP3A4*22, or Hematocrit, Predicts Tacrolimus Dose Requirements in Brazilian Renal Transplant Patients. Santoro, A B; Struchiner, C J; Felipe, C R; Tedesco‐Silva, H; Medina‐Pestana, J O; Suarez‐Kurtz, G // Clinical Pharmacology & Therapeutics;Aug2013, Vol. 94 Issue 2, p201 

    A letters to the editor is presented in response to articles "In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients" by de Jonge and colleagues in the previous issue.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics